Biomatics Capital related stories
All articles and analysis
VC-backed Verve Therapeutics goes publicVerve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
Verve Therapeutics scores $63mCambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has raised $63 million in Series A2 funding.
Variant Bio snags $16m Series AVariant Bio, a biotech startup, has secured $16 million in Series A funding.
- VC-backed Thrive Earlier Detection Corp appoints Franklin as chief commercial officer
Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a provider of earlier cancer detection solutions, has named Matt Franklin as chief commercial officer and Sarah Larson to its board of directors.
AI company AiCure takes in $24.5 mln Series CNew York City-based AiCure, an artificial intelligence company, has secured $24.5 million in Series C funding. Palisades Growth Capital led the round with participation from Singtel Innov8, Asahi Kasei Corporation, Accelmed Growth Partners, SpringRock Ventures, Baird Capital, New Leaf Venture Partners, the Pritzker Group, Biomatics Capital, Tribeca Venture Partners and Silicon Valley Bank.
- VC-backed Verve Therapeutics hires chief scientific officer
Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Bellinger as chief scientific officer. Dr. Bellinger is a general cardiologist at Brigham and Women’s Hospital. Verve’s backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
- VC-backed Thrive Earlier Detection adds new SVP to team
Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a healthcare company focused on incorporating earlier cancer detection into routine medical care, has named Seema Singh Bhan as senior vice president, public policy and external affairs. She is the former vice president, head of public policy for Foundation Medicine. Thrive Earlier Detection's backers include Third Rock Ventures, Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group and Exact Sciences.
- VC-backed Verve Therapeutics expands scientific advisory board with new addition
Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Geall to its scientific advisory board. Geall is vice president of formulations, analytics and chemistry at Avidity Biosciences. Verve's backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
- VC-backed Thrive Earlier Detection Corp taps Daly as CEO
Cambridge, Massachusetts and Baltimore-based Thrive Earlier Detection Corp, a healthcare company focused on incorporating earlier cancer detection into routine medical care, has named David J. Daly as CEO. Previously, Daly worked at Illumina, where he was the senior vice president and general manager of commercial operations for the Americas region. Thrive Earlier Detection Corp's backers include Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group and Exact Sciences.
- BlackThorn Therapeutics racks up $76 mln Series B
San Francisco-based BlackThorn Therapeutics, a neurobehavioral health company, has secured $76 million in Series B financing. The investors included Polaris Partners, Premier Partners, Scripps Research, Vertex Ventures HC, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation – JJDC, Inc. and Mercury Fund. In connection with the financing, Brian Chee, a managing partner at Polaris Partners, Lori Hu, a managing director at Vertex Ventures HC and Julie Sunderland, a managing director at Biomatics Capital, joined BlackThorn’s board as directors.